

Warts Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/W93033EF5DA2EN.html>

Date: March 2022

Pages: 92

Price: US\$ 2,000.00 (Single User License)

ID: W93033EF5DA2EN

Abstracts

Warts Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Warts - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Warts (Infectious Disease) pipeline landscape.

Warts are skin growth that is caused by virus called human papillomavirus (HPV). HPV infects the top layer of skin, usually entering the body in an area of broken skin. The virus causes the top layer of skin to grow rapidly, forming a wart. Symptoms include pain and rough skin. Predisposing factors include age and people with weakened immune systems, such as those with HIV/AIDS or people who had organ transplants.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Warts - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Warts (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Warts (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Warts and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 5, 17, 5, 2, 3 and 2 respectively. Similarly, the Universities portfolio in Phase II, and Preclinical stages comprises 1, and 2 molecules, respectively.

Warts (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Warts (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Warts (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Warts (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Warts (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Warts (Infectious Disease)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Warts (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Warts (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and

understand from the know-how what drove them from pipeline.

Contents

- Introduction
- Global Markets Direct Report Coverage
- Warts - Overview
- Warts - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Warts - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Warts - Companies Involved in Therapeutics Development
- Aclaris Therapeutics Inc
- Beijing Kangle Guardian Biotechnology Co Ltd
- Chengdu Institute of Biological Products Co Ltd
- Cutanea Life Sciences Inc
- Cytovation AS
- Douglas Pharmaceuticals Ltd
- Etna Biotech Srl
- Feramda Ltd
- G&E Herbal Biotechnology Co., Ltd.
- Genetic Immunity Inc
- Guangzhou Cape Biological Technology Co Ltd
- Hefei Ruichengsheng Biotechnology Co Ltd
- KinoPharma Inc
- Laboratories Ojer Pharma SL
- Maruho Co Ltd
- Merck & Co Inc
- Nielsen Biosciences Inc
- Novan Inc
- Orgenesis Inc
- Peritech Pharma
- Phio Pharmaceuticals Corp
- Shanghai Bovax Biotechnology Co Ltd

Shanghai Zerun Biotechnology Co Ltd

SinoCelltech Group Ltd

Veloce BioPharma LLC

Verrica Pharmaceuticals Inc

Xiamen Innovax Biotech Co Ltd

Warts - Drug Profiles

(lopinavir + ritonavir) - Drug Profile

Product Description

Mechanism Of Action

Albicin - Drug Profile

Product Description

Mechanism Of Action

History of Events

AS-101 - Drug Profile

Product Description

Mechanism Of Action

History of Events

cantharidin - Drug Profile

Product Description

Mechanism Of Action

History of Events

Cellular Immunotherapy for Condyloma - Drug Profile

Product Description

Mechanism Of Action

History of Events

Cellular Immunotherapy for Human Papillomavirus Infections - Drug Profile

Product Description

Mechanism Of Action

chloroquine phosphate - Drug Profile

Product Description

Mechanism Of Action

CyPep-1 - Drug Profile

Product Description

Mechanism Of Action

FIT-039 - Drug Profile

Product Description

Mechanism Of Action

History of Events

human papillomavirus (9 valent) vaccine - Drug Profile

Product Description

Mechanism Of Action

History of Events

human papillomavirus (9 valent) vaccine - Drug Profile

Product Description

Mechanism Of Action

History of Events

human papillomavirus (9-valent) vaccine - Drug Profile

Product Description

Mechanism Of Action

History of Events

human papillomavirus [serotypes 6, 11, 16, 18, 31, 33, 45, 52 and 58] (9-valent) vaccine - Drug Profile

Product Description

Mechanism Of Action

History of Events

human papillomavirus [serotypes 6, 11, 16, 18] (quadrivalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

History of Events

human papillomavirus [serotypes 6, 11] (bivalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

History of Events

human papillomavirus [serotypes 6, 11] (bivalent, virus like particle) vaccine - Drug Profile

Product Description

Mechanism Of Action

human papillomavirus [serotypes 6,11,16,18,31,33,45,52,58,59 and 68] (11-valent) vaccine - Drug Profile

Product Description

Mechanism Of Action

human papillomavirus [serotypes 6,11,16,18,31,33,45,52,58] (9-valent) vaccine - Drug Profile

Product Description

Mechanism Of Action

human papillomavirus vaccine - Drug Profile

Product Description

Mechanism Of Action

human papillomavirus vaccine (tetravalent) - Drug Profile

Product Description

Mechanism Of Action

History of Events

HupaDerm - Drug Profile

Product Description

Mechanism Of Action

History of Events

hydrogen peroxide - Drug Profile

Product Description

Mechanism Of Action

History of Events

imiquimod SR - Drug Profile

Product Description

Mechanism Of Action

interferon alfa-2b - Drug Profile

Product Description

Mechanism Of Action

omiganan pentahydrochloride - Drug Profile

Product Description

Mechanism Of Action

History of Events

pefcalcitol - Drug Profile

Product Description

Mechanism Of Action

History of Events

PP-210 - Drug Profile

Product Description

Mechanism Of Action

ranpirnase - Drug Profile

Product Description

Mechanism Of Action

History of Events

RKP-00156 - Drug Profile

Product Description

Mechanism Of Action

Samcyprone - Drug Profile

Product Description

Mechanism Of Action

History of Events

SB-206 - Drug Profile

Product Description

Mechanism Of Action

History of Events

SB-207 - Drug Profile

Product Description

Mechanism Of Action

SCT-1000 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules for Human Papillomavirus Infections - Drug Profile

Product Description

Mechanism Of Action

SRT-100 - Drug Profile

Product Description

Mechanism Of Action

History of Events

VBP-245 - Drug Profile

Product Description

Mechanism Of Action

History of Events

VP-103 - Drug Profile

Product Description

Mechanism Of Action

Warts - Dormant Projects

Warts - Discontinued Products

Warts - Product Development Milestones

Featured News & Press Releases

Jan 19, 2021: Verrica Pharmaceuticals presents positive data from clinical studies evaluating the safety and efficacy of VP-102 in molluscum and external genital warts at the 2021 Winter Clinical Dermatology Conference

Nov 10, 2020: Verrica Pharmaceuticals announces positive topline results in Phase 2 clinical study of VP-102 in patients with external genital warts (CARE-1)

Oct 24, 2019: Aclaris Therapeutics A-101 45% topical solution meets primary and all secondary efficacy endpoints in second successful pivotal phase 3 clinical trial for the treatment of common warts (THWART-1)

Oct 18, 2019: Novan further expands its proprietary nitric oxide platform

Oct 18, 2019: Verrica Pharmaceuticals announces presentation of positive data from clinical trials of VP-102 at the 2019 39th Annual Fall Clinical Dermatology Conference

Sep 16, 2019: Aclaris Therapeutics A-101 45% Topical Solution meets primary and all secondary efficacy endpoints in pivotal phase 3 trial for the treatment of common warts (THWART-2)

Jul 24, 2019: Novan's drug substance demonstrates inhibition of HPV-18 virus production

Jun 27, 2019: Verrica Pharmaceuticals enrolls first patient in Phase 2 trial of VP-102 for the treatment of external genital warts

Jun 26, 2019: Verrica Pharmaceuticals achieves positive topline results in phase 2 clinical study of VP-102 in [patients with common warts

Mar 18, 2019: Cytovation initiates clinical development programme with CyPep-1, a first-in-class lytic agent for tumor immunotherapy

Feb 19, 2019: Aclaris Therapeutics to present scientific posters at the 77th Annual Meeting of the American Academy of Dermatology

Nov 01, 2018: Novan Publication Supports Women's Health Business Unit Initiative and Nitric Oxide's Potential Against HPV-Associated Diseases

Sep 24, 2018: Aclaris Therapeutics Announces First Patient Dosed in Phase 3 Studies Evaluating A-101 45% in Patients with Common Warts

Jul 19, 2018: Cassiopea announces top line positive proof of concept phase II results for CB-06-02 immune modulator in treating genital warts

May 18, 2018: RXi Pharmaceuticals Announces Positive Results from Phase 2 Trial with Samcyprone for the Treatment of Common Warts

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Warts, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Warts - Pipeline by Aclaris Therapeutics Inc, 2022
Warts - Pipeline by Beijing Kangle Guardian Biotechnology Co Ltd, 2022
Warts - Pipeline by Chengdu Institute of Biological Products Co Ltd, 2022
Warts - Pipeline by Cutanea Life Sciences Inc, 2022
Warts - Pipeline by Cytovation AS, 2022
Warts - Pipeline by Douglas Pharmaceuticals Ltd, 2022
Warts - Pipeline by Etna Biotech Srl, 2022
Warts - Pipeline by Feramda Ltd, 2022
Warts - Pipeline by G&E Herbal Biotechnology Co., Ltd., 2022
Warts - Pipeline by Genetic Immunity Inc, 2022
Warts - Pipeline by Guangzhou Cape Biological Technology Co Ltd, 2022
Warts - Pipeline by Hefei Ruichengsheng Biotechnology Co Ltd, 2022
Warts - Pipeline by KinoPharma Inc, 2022
Warts - Pipeline by Laboratories Ojer Pharma SL, 2022
Warts - Pipeline by Maruho Co Ltd, 2022
Warts - Pipeline by Merck & Co Inc, 2022
Warts - Pipeline by Nielsen Biosciences Inc, 2022
Warts - Pipeline by Novan Inc, 2022
Warts - Pipeline by Orgenesis Inc, 2022
Warts - Pipeline by Peritech Pharma, 2022
Warts - Pipeline by Phio Pharmaceuticals Corp, 2022
Warts - Pipeline by Shanghai Bovax Biotechnology Co Ltd, 2022
Warts - Pipeline by Shanghai Zerun Biotechnology Co Ltd, 2022
Warts - Pipeline by SinoCelltech Group Ltd, 2022

Warts - Pipeline by Veloce BioPharma LLC, 2022
Warts - Pipeline by Verrica Pharmaceuticals Inc, 2022
Warts - Pipeline by Xiamen Innovax Biotech Co Ltd, 2022
Warts - Dormant Projects, 2022
Warts - Dormant Projects, 2022 (Contd..1)
Warts - Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Warts, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022

I would like to order

Product name: Warts Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/W93033EF5DA2EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/W93033EF5DA2EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

